Overview

Nurse's Role in the Management of Hyperprolactinemia

Status:
Recruiting

Trial end date:
2020-05-01

Target enrollment:
0

Participant gender:
Female

Summary

Many women despite being well-treated in proper dose, with proper drug and for proper duration, may not respond to different forms of prolactin normalizing drugs. This will lead to extension of the treatment duration up to months or even years. Doctors usually increase the dose of the drug with high possibility of side effects and even complications. Some doctors change drug group to another without any significant improvement of hyperprolactinemia. hyperprolactinemia can indicate a deeper issue, about 10 percent of the population has hyperprolactinemia. Life style, feeding habits and sexual behaviors are usually not included in the management protocols of hyperprolactinemia. Aim of the study: This study will be aimed to: 1. Evaluate the effect of nursing role in the management of hyperprolactinemia. 2. Give health education for women underlying forms of prolactin normalizing drugs for hyperprolactinemia. Hypothesis of the study: H1- Health education for women under drugs of hyperprolactinemia is effective in reduce level of prolactine. H0- Health education for women under drugs of hyperprolactinemia is not effective in reduce level of prolactin

Phase:

Phase 1

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Woman's Health University Hospital, Egypt

Treatments:

Cabergoline

Criteria

Inclusion criteria:

1. Pathologic hyperprolactinemia due to any cause.

2. Non-pregnant.

3. Not lactating.

Exclusion criteria:

1. Physiologic hyperprolactinemia.

2. Women who don't consent for follow up.